[1] Gao J, Qiao L, Wang B. Primary biliary cirrhosis is a generalized autoimmune epithelitis. Int J Mol Sci, 2015, 16: 6432-6446.
[2] Corrigan M, Hirschfield GM. Primary biliary cirrhosis. Medicine, 2015, 8: 12.
[3] Wang YH, Yang W, Yang JB, et al. Systems biologic analysis of T regulatory cells genetic pathways inmurine primary biliary cirrhosis. J Autoimmun, 2015, 59: 26-37.
[4] Craig L, Douglas LN, Brian DJ, et al. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Digest Liver Dis, 2013, 45: 589-594.
[5] Brian DJ,Konstantinos NL. Environmental Factors in Primary Biliary Cirrhosis. Semin Liver Dis, 2014, 34: 265-272.
[6] Vasiliy IR. Primary biliary cirrhosis: Clinical and laboratory criteria forits diagnosis. World J Gastroenterol, 2015, 21: 7683-7708.
[7] Zhang XX, Wang LF, Jin L, et al. Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors. World J Gastroenterol, 2015, 21: 3554-3563.
[8] Zhang W,Wang L,Wang LQ,et al. 1039 hidden source sex hepatitis patients AMA - M2 antibody screening. Hepatology, 2012, 15: 238-240.
[9] Bernuzzi F,Fenoglio D,Battaglia F,et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun, 2010, 35: 176-180.
[10] Zhang WC,Yoko O,Yoshinori M. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J Autoimmun, 2011, 37: 71-78.
[11] Lv K, Zhang Y, Zhang M, et al. Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4(+)CD25(low/int) effector T-Cell apoptosis and increasing regulatory T cell number. Plos One, 2012, 7: 48-53.
[12] Kenichi H, Judy VD, Patrick SC, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology, 1997, 2: 791-796.
[13] Abe M, Hiasa Y, Onji M. T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol, 2013, 9: 70-73.
[14] Ye Y, Xie X, Yu J, et al. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Allergy Clin Immun, 2010, 30: 546-555.
[15] Kawata K, Tsuda M, Yang GX, et al. Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis. PloS One. 2013, 8: 1-11.
[16] Christopher AA,Chaim MR,Lian ZX,et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun, 2006, 27: 50-53.
[17] Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepaticautoimmunity. J Autoimmun, 2016, 66: 25-39.
[18] Ana L, Gershwin ME,Alberto M, et al. Towards common denominators in primary biliary cirrhosis: The role of IL-12. Hepatology, 2012, 56: 731-733.
[19] Yang JB, Wang YH, Yang W. Successful treatment of murine autoimmune cholangitis by parabiosis: Implications for hematopoietic therapy. J Autoimmun, 2015, 1: 1-10.
[20] Li H, Wang WW, Wang GY. Interferon-r and tumor necrosis factor- a promote the ability of human placentae-derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4+interleukin-10+and CD8+interleukin-10+Treg subsets. Cytotherapy, 2015, 17: 1560-1571.
[21] Chang CH, Chen YH, Zhang WC, et al.Innate immunity drives the initiation of a murine model of primary biliary cirrhosis. Plos One, 2015, 10: 1-13.
[22] Ana L, Pietro I, Mackay IR, et al.Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol, 2008, 14: 3328-3337.
[23] Qian C, Jiang T, Zhang W, et al. Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis. Cytokine, 2013, 64: 172-180.
[24] Wanrooij RL, Zwiers A, Kraal G, et al. Genetic variations in interleukin-12 related genes in immune-mediated diseases. J Autoimmun, 2012, 39: 359-368.
[25] Yvon C,Raoul P. Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases. Clin Res Hepatol Gastroenterol, 2014, 38: 550-556.
[26] Liu XD, Pietro I, Lu Y, et al.Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet, 2010, 42: 658-660.
[27] Katsunori Y, Yang GX, Zhang WC, et al.Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor receptor Type II Mice. Hepatology, 2009, 50: 1-7.
[28] Yao Y, Yang W, Yang YQ. Distinct from its canonical effects,deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ra -/- mice. J Autoimmun, 2014, 51: 99-108.
[29] Masanobu T, Zhang WC, Yang GX, et al. Deletion of IL-12p35 induces liver fibrosis in dominant negative transforming growth factor β receptor type II mice. Hepatology, 2013, 57: 806-816.
[30] Xia R, Tang YJ, Huang YJ. TNFSF9 expression in primary biliary cirrhosis and its clinical significance. Cytokine, 2010, 50: 311-316.
[31] Yamano T, Higashi T, Nouso K, et al. Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol, 2000, 122: 227-231.
[32] Santodomingo GT, Swain MG. Role of NKT cells in autoimmune liver disease. Autoimmunity Rev, 2011, 10: 793-800.
[33] Tsuda M, Zhang W, Yang GX, et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type II mice. Hepatology, 2013, 57: 806-816.
[34] Dale IG, Kirsten JL, Lynn DP. NKT cells: Facts, functions and fallacies. Immunology Today, 2000, 21: 573-583.
[35] Zen Y, Liberal R, Nakanuma Y, et al. Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. Hepatology, 2013, 59: 1059-1064.
[36] Wakabayashi K, Lian ZX, Moritoki Y, et al. IL-2 Receptor -/- Mice and the Development of Primary Biliary Cirrhosis. Hepatology, 2006, 44: 1240-1249.
[37] Web GJ, Siminovitch KA, Hirschfield GM.The immunogenetics of primary biliary cirrhosis: A comprehensive review. J Autoimmun, 2015, 1: 1-10.
[38] Lan RY, Salunga TL, Tsuneyama K, et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J autoimmun, 2009, 32: 43-51.
[39] Masanobu T, Yoko MA, Zhang WC. Fine phenotypic and functional characterization of effector CD8 +T cells in patients with Primary Biliary Cirrhosis. Hepatology, 2011, 54: 1293-1302.
[40] Ruth YZ, Thucydides LS, Koichi T,et al. Hepatic IL-17 Responses in Human and Murine Primary Biliary Cirrhosis. J Autoimmun, 2009, 32: 43-51.
[41] Kimchi N, Charlotte DM, Tai L. Regulatory T cells suppress sickness behaviour developmentwithout altering liver injury in cholestatic mice. Hepatology, 2012, 56: 626-631.
[42] Wang L, Du HH, Zhang W, et al. In patients with primary biliary cirrhosis liver estrogen receptor and peripheral blood cell factors and the correlation study of autoantibodies. Hepatology, 2012, 20: 336-339.
[43] Ruth YL, Patrick L, Aftab AA. Solving the primary biliary cirrhosis puzzle: The emerging image of immunopathology in primary biliary cirrhosis. ClinAppl Immunol Rev, 2005, 5: 271-284.
[44] 韩志君,孙懿,严子禾.IL-27介导的炎症反应在原发性胆汁性肝硬化中的作用. 中华微生物学和免疫学杂志,2010,30: 755-759. |
